Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Angela L Stotts, Carrie L Dodrill & Thomas R Kosten. (2009) Opioid dependence treatment: options in pharmacotherapy. Expert Opinion on Pharmacotherapy 10:11, pages 1727-1740.
Read now
Read now
Wendy Kissin, Caroline McLeod, Joseph Sonnefeld & Arlene Stanton. (2006) Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence. Journal of Addictive Diseases 25:4, pages 91-103.
Read now
Read now
DonaldR. Wesson. (2004) Buprenorphine in the Treatment of Opiate Dependence: Its Pharmacology and Social Context of Use in the U.S.. Journal of Psychoactive Drugs 36:sup2, pages 119-128.
Read now
Read now
David A. Fiellin, Patrick G. O'Connor, Marek Chawarski & Richard S. Schottenfeld. (2004) Processes of Care During a Randomized Trial of Office-based Treatment of Opioid Dependence in Primary Care. American Journal on Addictions 13:sup1, pages S67-S78.
Read now
Read now
David A. Fiellin, Michael V. Pantalon, Juliana P. Pakes, Patrick G. O'Connor, Marek Chawarski & Richard S. Schottenfeld. (2002) Treatment of heroin dependence with buprenorphine in primary care. The American Journal of Drug and Alcohol Abuse 28:2, pages 231-241.
Read now
Read now
DavidC. Lewis. (1999) Access to Narcotic Addiction Treatment and Medical Care. Journal of Addictive Diseases 18:2, pages 5-21.
Read now
Read now
Articles from other publishers (33)
Megan Buresh, Robert Stern & Darius Rastegar. (2021) Treatment of opioid use disorder in primary care. BMJ, pages n784.
Crossref
Crossref
Lisa de Saxe Zerden, Ting Guan, Brianna M. Lombardi, Anjalee Sharma & Yazmin Garcia-Rico. (2020) Psychosocial Interventions in Office-Based Opioid Treatment: A Systematic Review. Journal of the Society for Social Work and Research 11:1, pages 103-131.
Crossref
Crossref
Thomas GeschwindeThomas Geschwinde. 2018. Rauschdrogen. Rauschdrogen
791
1000
.
Elizabeth A. Mayerson & Thomas Julian. (2017) Acute Pain Management for Patients on Medication-Assisted Treatment for Opioid-Use Disorder. Topics in Pain Management 33:3, pages 1-10.
Crossref
Crossref
Franchesca Arias, Julia H. Arnsten, Chinazo O. Cunningham, Kelly Coulehan, Abigail Batchelder, Mia Brisbane, Katie Segal & Monica Rivera-Mindt. (2016) Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults. Addictive Behaviors 60, pages 137-143.
Crossref
Crossref
Caner Mutlu, Arzu Ciftci Demirci, Ozhan Yalcin, Ali Guven Kilicoglu, Melike Topal & Gul Karacetin. (2016) One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorfine/Naloxone for the First Time in a Substance Treatment Unit. Journal of Substance Abuse Treatment 67, pages 1-8.
Crossref
Crossref
Steven C. Matson, Gerrit Hobson, Mahmoud Abdel-Rasoul & Andrea E. Bonny. (2014) A Retrospective Study of Retention of Opioid-Dependent Adolescents and Young Adults in an Outpatient Buprenorphine/Naloxone Clinic. Journal of Addiction Medicine 8:3, pages 176-182.
Crossref
Crossref
Thomas GeschwindeThomas Geschwinde. 2013. Rauschdrogen. Rauschdrogen
647
830
.
Lisa J. Merlo, Kimberly G. Blumenthal, Kendall Campbell, Morrow Omli & Mark S. Gold. 2010. Addictive Disorders in Medical Populations. Addictive Disorders in Medical Populations
503
523
.
Patrizia Amato. (2010) Clinical Experience with Fortnightly Buprenorphine/Naloxone versus Buprenorphine in Italy. Clinical Drug Investigation 30, pages 33-39.
Crossref
Crossref
C. Roncero, N. Sáez-Francàs, X. Castells & M. Casas. (2008) Eficacia y manejo clínico de la buprenorfina. Trastornos Adictivos 10:2, pages 77-87.
Crossref
Crossref
Erik W Gunderson & David A Fiellin. (2008) Office-Based Maintenance Treatment of Opioid Dependence. CNS Drugs 22:2, pages 99-111.
Crossref
Crossref
Alethea A. Varra & Steven C. Hayes. (2007) Assessing referrals for pharmacotherapy: A comparison of therapist and client report. Journal of Substance Abuse Treatment 32:4, pages 411-413.
Crossref
Crossref
. 2007. Rauschdrogen. Rauschdrogen
603
762
.
Kenneth A. HarrisJrJr, Julia H. Arnsten, Herman Joseph, Joe Hecht, Ira Marion, Patti Juliana & Marc N. Gourevitch. (2006) A 5-year evaluation of a methadone medical maintenance program. Journal of Substance Abuse Treatment 31:4, pages 433-438.
Crossref
Crossref
Christian Haasen & Wim van den Brink. (2006) Innovations in agonist maintenance treatment of opioid-dependent patients. Current Opinion in Psychiatry 19:6, pages 631-636.
Crossref
Crossref
Wim van den Brink & Christian Haasen. (2006) Evidence-Based Treatment of Opioid-Dependent Patients. The Canadian Journal of Psychiatry 51:10, pages 635-646.
Crossref
Crossref
David A. Fiellin, Michael V. Pantalon, Marek C. Chawarski, Brent A. Moore, Lynn E. Sullivan, Patrick G. O'Connor & Richard S. Schottenfeld. (2006) Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence. New England Journal of Medicine 355:4, pages 365-374.
Crossref
Crossref
Walter Ling & Peggy Compton. (2005) Recent advances in the treatment of opiate addiction. Clinical Neuroscience Research 5:2-4, pages 161-167.
Crossref
Crossref
C. Roncero & M. Casas. (2005) Eficacia clínica de la buprenorfina. Trastornos Adictivos 7:1, pages 23-26.
Crossref
Crossref
David A. Fiellin, Herbert Kleber, Jeanne G. Trumble-Hejduk, A. Thomas McLellan & Thomas R. Kosten. (2004) Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment 27:2, pages 153-159.
Crossref
Crossref
Wim van den Brink & Jan M. van Ree. (2003) Pharmacological treatments for heroin and cocaine addiction. European Neuropsychopharmacology 13:6, pages 476-487.
Crossref
Crossref
Wim van den Brink, Marian Goppel & Jan M. van Ree. (2003) Management of opioid dependence. Current Opinion in Psychiatry 16:3, pages 297-304.
Crossref
Crossref
Wim van den Brink, Marian Goppel & Jan van Ree. (2003) Current Opinion in Psychiatry 16:3, pages 297-304.
Crossref
Crossref
Thomas GeschwindeThomas Geschwinde. 2003. Rauschdrogen. Rauschdrogen
511
641
.
Elinore F. McCance‐Katz, Petrie M. Rainey, Gerald Friedland, Thomas R. Kosten & Peter Jatlow. (2010) Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. The American Journal on Addictions 10:4, pages 296-307.
Crossref
Crossref
Jean Vignau, Alain Duhamel, Jacques Catteau, Guy Legal, Anh Huynh, Isabelle Grailles, Jacques Beauvillain, Philippe Petit, Pierre Beauvillain & Philippe J Parquet. (2001) Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients?. Journal of Substance Abuse Treatment 21:3, pages 135-144.
Crossref
Crossref
Michael Agar, Philippe Bourgois, John French & Owen Murdoch. (2016) Buprenorphine: “Field Trials” of a New Drug. Qualitative Health Research 11:1, pages 69-84.
Crossref
Crossref
Rolley E. Johnson & Jeffrey C. McCagh. (2000) Buprenorphine and Naloxone for Heroin Dependence. Current Psychiatry Reports 2:6, pages 519-526.
Crossref
Crossref
KEVIN A. SEVARINO, ALISON OLIVETO & THOMAS R. KOSTEN. (2006) Neurobiological Adaptations to Psychostimulants and Opiates as a Basis of Treatment Development. Annals of the New York Academy of Sciences 909:1, pages 51-87.
Crossref
Crossref
Marc A. SchuckitMarc A. Schuckit. 2000. Drug and Alcohol Abuse. Drug and Alcohol Abuse
305
348
.
M.C. Chawarski, R.S. Schottenfeld, P.G. O’Connor & J. Pakes. (1999) Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug and Alcohol Dependence 55:1-2, pages 157-163.
Crossref
Crossref
PatrickG O’Connor, AlisonH Oliveto, JuliaM Shi, ElisaG Triffleman, KathleenM Carroll, ThomasR Kosten, BruceJ Rounsaville, JulianaA Pakes & RichardS Schottenfeld. (1998) A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. The American Journal of Medicine 105:2, pages 100-105.
Crossref
Crossref